<p>A label-free electrochemical immunosensor for carcinoembryonic antigens (CEA) detection is reported based on a built-in thiol-mesoporous carbon architecture. The material was functionalized with 3-maleimidepropionic acid to immobilize anti-CEA antibodies. The immunosensor was characterized using field-emission scanning electron microscopy, X-ray photoelectron spectroscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. Biorecognition events were monitored by differential pulse voltammetry, with current intensity dependent on protein concentration. The device exhibited a linear range of 1–10 ng mL<sup>-1</sup> for CEA, with a clinically relevant limit of detection of 1.02 ng mL<sup>-1</sup>. The immunosensor successfully detected CEA in human serum samples, with results comparable to those obtained by a standard spectrophotometric method. This platform has proven to be a promising alternative for the prognosis and management of patients with colorectal cancer, as well as having significant potential for point-of-care diagnosis.</p> Graphical Abstract <p></p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Built-in thiol mesoporous carbon immunosensor to detect carcinoembryonic antigen in human serum

  • Danilo Echeverri,
  • Jennifer Laverde,
  • Luis Gerónimo Restrepo,
  • Nestor Llinás-Quintero,
  • Diana López,
  • Jahir Orozco

摘要

A label-free electrochemical immunosensor for carcinoembryonic antigens (CEA) detection is reported based on a built-in thiol-mesoporous carbon architecture. The material was functionalized with 3-maleimidepropionic acid to immobilize anti-CEA antibodies. The immunosensor was characterized using field-emission scanning electron microscopy, X-ray photoelectron spectroscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. Biorecognition events were monitored by differential pulse voltammetry, with current intensity dependent on protein concentration. The device exhibited a linear range of 1–10 ng mL-1 for CEA, with a clinically relevant limit of detection of 1.02 ng mL-1. The immunosensor successfully detected CEA in human serum samples, with results comparable to those obtained by a standard spectrophotometric method. This platform has proven to be a promising alternative for the prognosis and management of patients with colorectal cancer, as well as having significant potential for point-of-care diagnosis.

Graphical Abstract